AIM OF STUDY: To examine the impact of survival probability according to duration of survivorship following radical cystectomy (RC) in patients diagnosed with urothelial carcinoma of the urinary bladder (UCUB). METHODS: Overall, 4991 UCUB patients who underwent RC were abstracted. The cumulative survival estimates were used to generate conditional survival rates. Cox regression analyses were performed for prediction of cancer-specific mortality (CSM), according to duration of survivorship. RESULTS: The five-year CSM-free survival rate was 63.9% at RC, and increased to 71.0%, 77.5%, 81.7%, 85.9% and 86.3% in patients who survived ≥ 1, 2, 3, 4 and 5 years, respectively. Patients with pT2-4 disease benefitted from the highest increase in survivorship two years after RC. The same findings were recorded according to patients' nodal status. CONCLUSION: The survival of the first two years after RC markedly improves individual patient prognosis. The prognostic gains differ according to patient and tumour characteristics. Crown
AIM OF STUDY: To examine the impact of survival probability according to duration of survivorship following radical cystectomy (RC) in patients diagnosed with urothelial carcinoma of the urinary bladder (UCUB). METHODS: Overall, 4991 UCUB patients who underwent RC were abstracted. The cumulative survival estimates were used to generate conditional survival rates. Cox regression analyses were performed for prediction of cancer-specific mortality (CSM), according to duration of survivorship. RESULTS: The five-year CSM-free survival rate was 63.9% at RC, and increased to 71.0%, 77.5%, 81.7%, 85.9% and 86.3% in patients who survived ≥ 1, 2, 3, 4 and 5 years, respectively. Patients with pT2-4 disease benefitted from the highest increase in survivorship two years after RC. The same findings were recorded according to patients' nodal status. CONCLUSION: The survival of the first two years after RC markedly improves individual patient prognosis. The prognostic gains differ according to patient and tumour characteristics. Crown
Authors: Aristotelis Bamias; Kimon Tzannis; Christina Bamia; Lauren C Harshman; Simon Crabb; Elizabeth R Plimack; Sumanta Pal; Ugo De Giorgi; Sylvain Ladoire; Christine Theodore; Neeraj Agarwal; Evan Y Yu; Guenter Niegisch; Cora N Sternberg; Sandy Srinivas; Ulka Vaishampayan; Andrea Necchi; Michalis Liontos; Jonathan E Rosenberg; Thomas Powles; Joaquim Bellmunt; Matthew D Galsky Journal: Oncologist Date: 2019-04-01
Authors: Francesco Alessandro Mistretta; Carlotta Palumbo; Sophie Knipper; Elio Mazzone; Angela Pecoraro; Zhe Tian; Gennaro Musi; Paul Perrotte; Emanuele Montanari; Shahrokh F Shariat; Fred Saad; Alberto Briganti; Ottavio de Cobelli; Pierre I Karakiewicz Journal: World J Urol Date: 2019-07-11 Impact factor: 4.226
Authors: Yuhree Kim; Georgios A Margonis; Jason D Prescott; Thuy B Tran; Lauren M Postlewait; Shishir K Maithel; Tracy S Wang; Jason A Glenn; Ioannis Hatzaras; Rivfka Shenoy; John E Phay; Kara Keplinger; Ryan C Fields; Linda X Jin; Sharon M Weber; Ahmed Salem; Jason K Sicklick; Shady Gad; Adam C Yopp; John C Mansour; Quan-Yang Duh; Natalie Seiser; Carmen C Solorzano; Colleen M Kiernan; Konstantinos I Votanopoulos; Edward A Levine; George A Poultsides; Timothy M Pawlik Journal: Ann Surg Date: 2017-01 Impact factor: 12.969
Authors: Marco Moschini; Agostino Mattei; Julian Cornelius; Shahrokh F Shariat; Paolo Dell'Oglio; Emanuele Zaffuto; Andrea Salonia; Francesco Montorsi; Alberto Briganti; Renzo Colombo; Andrea Gallina Journal: World J Urol Date: 2018-01-24 Impact factor: 4.226
Authors: Sumanta Kumar Pal; Yulan Ingrid Lin; Bertram Yuh; Kara DeWalt; Austin Kazarian; Nicholas Vogelzang; Rebecca A Nelson Journal: PLoS One Date: 2015-08-26 Impact factor: 3.240
Authors: Brady L Miller; E Jason Abel; Glenn Allen; Jessica R Schumacher; David Jarrard; Tracy Downs; Kyle A Richards Journal: Am J Clin Exp Urol Date: 2020-02-25